3. Introduction
Heart failure (HF) is a complex clinical
syndrome that can result from any structural
or functional cardiac disorder that impairs the
ability of the ventricle to fill with or eject
blood
No longer use the term “congestive” because
all heart failure does not result in clinically
apparent volume overload
4. How to define heart failure?
Systolic Versus Diastolic Heart Failure
A. Systolic cardiac (heart) dysfunction (or
systolic heart failure) occurs when the heart
muscle doesn't contract with enough force,
so there is not enough oxygen-rich blood to
be pumped throughout the body.
B. Diastolic cardiac dysfunction (or diastolic
heart failure) occurs when the heart
contracts normally, but the ventricle doesn't
relax properly so less blood can enter the
heart.
5. What is the incidence of heart failure?
Estimated 500,000 new cases per year
Within 5 years, half of those diagnosed will be
dead
Over 1 million hospitalizations per year with
HF as primary diagnosis
Most common reason for hospitalization in
those >65 years old
Heart failure is 4th in a list of quality of care
initiatives in vulnerable older adults
6. Case-Mr Abdallah
45 yr old man with poorly controlled
hypertension, DM presents with 3 weeks of
progressive shortness of breath, LE edema
Exam remarkable for HR 150, BP 80/40, RR 26
Appears lethargic, Elevated JVP, PMI displaced,
irregular, S1, S2, S3 on exam, no murmurs, lungs
with crackles, Extremities cold with edema
10. Back to our patient
So Mr Abdallah has risk factors for CAD
Also has elevated BP-so hypertensive heart
No murmur on exam so valvular heart disease
unlikely
Arrythmias……..afib, tachycardia induced
cardiomyopathy
What about amyloidosis
ALWAYS LOOK FOR REVERSIBLE CAUSES
12. Initial Workup
Basic labs, check for anemia-high output
failure, chem8, TSH, ferritin
EKG-look for acute MI or prior infarcts
CXR- pulmonary edema, heart size
Echocardiogram to assess LV function, assess
for diastolic dysfunction
13. Future workup
Coronary Angiogram
If flash pulmonary edema and severe HTN,
consider renal angiogram
If no clear cause in young patient consider
cardiac biopsy
14. Mr Abdallah tests showed
Normal CBC
Elevated BUN/Creatinine 45/1.8
Elevated LFTS ( AST/ALT)
CXR showed pulmonary edema
Echo showed an EF of 30% with diffuse global
hypokinesis
17. Acute Treatment
Congestion?
Orthopnea, rales, JVD, edema, ascites
Warm and Dry Warm and Wet
Adequate
perfusion
Lethargy,
cool, pulse
pressure
Cold and Dry Cold and Wet
(Mr Abdallah)
Nohria, A. et al. JAMA 2002;287:628-640
18. Cardiogenic Shock
(Cold and Wet)
1. Systemic Hypotension
systolic arterial pressure < 80 mmHg
2. Persistent Hypotension
at least 30 minutes
3. Reduced Systolic Cardiac Function
Cardiac index < 1.8 x m²/min
4. Tissue Hypoperfusion
Oliguria, cold extremities, confusion
5. Increased Left Ventricular Filling
Pulmonary capillary wedge pressure >
18mmHg mmHg
19. Choice of Ionotropes
Dopamine
<2 renal vascular dilation
<2-10 +chronotropic/inotropic (beta effects)
>10 vasoconstriction (alpha effects)
Dobutamine – positive inotrope, vasodilates,
arrhythmogenic at higher doses
Norepinephrine (Levophed): vasoconstriction,
inotropic stimulant. Should only be used for
refractory hypotension with dec SVR.
Vasopression – vasoconstriction
VASO and LEVO should only be used as a last
resort
20. If patient tachycardic, dopamine and
dobutamine are not great choices
So in Mr Abdallah would attempt to
cardiovert him as he will not sustain pressor
support
TEE to r/o left atrial appendage thrombus
Followed by Cardioversion
21. So Mr Abdallah underwent TEE
Was cardioverted
BP improved
HR stabilized
Still congested but now hemodynamically
stable
NOW WHAT??
23. Furosemide Dosing
If patient is lasix naive start slow and titrate
up per urine output
Lasix dose usually 0.5-1mg/kg twice a day
Usually expect response in first 5-10mins with
IV
Usual start dose 40mg or 80mg IV q8hrs
Always give potassium supplements when
diuresing patient
24. Regular monitoring of electrolytes with IV
diuresis
Switch to PO when more euvolemic,
BUN/creatinine start rising
Remember 80mg PO =40mg IV
If patient already on PO lasix e.g 80mg PO
would start treating with higher IV dose (ie
80mg IV)
If poor response to lasix add thiazide diuretic
25. ACEI and Beta Blockers
Start ACEI in patients as soon
hemodynamically stable
Help reduce preload and afterload
Titrate up per patient, don’t look at BP!!
Beta Blockers-start low dose prior to discharge
Titrate dose as outpatient
26.
27. Back to Mr Abdallah
So Mr Abdallah is doing well, he maintained
sinus rhythm and is being discharged
What medications should he be on long term
for a mortality benefit??
29. Beta Blockers
34% reduction in all mortality with use of
beta-blockers
Decrease Cardiac Sympathetic Activity
Titrate slowly
Contraindications-bradycardia, heart block or
hemodynamic instability
Mild asthma is not a contraindication
Work irrespective of the etiology of the heart
failure
30. Three beta-blockers
Bisoprolol (Zebeta) -Trial CIBIS-II
Metoprolol (Toprol XL) –Trial MERIT-HF
(sustained release)
Carvedilol (Coreg) Trial-COPERNICUS
6 RCT’s with > 9,000 pts already taking ACE-I
showed a significant reduction in total
mortality and sudden death (NNT 24, and 35
over 1-2 years) regardless of severity
31.
32. Carvedilol vs. Metoprolol (COMET
2003)
3029 pts; carvedilol 25mg bid vs.
metoprolol 50 mg bid
Patient with NYHA Classes II-IV
Carvedilol –greater reduction in mortality
(NNT, 18 over 5 years) and cardiovascular
mortality (NNT, 16 over 5 years) than
metoprolol but hypotension was greater in
carvedilol (14 vs 11 percent)
33. Beta Blockers and concomitant
disease
Beta blocker therapy is recommended in the
great majority of patients with HF and
reduced LVEF—even if there is concomitant
diabetes, chronic obstructive lung disease or
peripheral vascular disease.
Use with caution in patients with:
Diabetes with recurrent hypoglycemia
Asthma or resting limb ischemia.
Use with considerable caution in patients with marked
bradycardia (<55 bpm) or marked hypotension (SBP < 80
mmHg).
Not recommended in patients with asthma with active
bronchospasm.
34. HFSA 2010 Practice Guideline ACE
Inhibitors
ACE inhibitors are recommended for
symptomatic and asymptomatic patients
with an LVEF ≤ 40%
ACE inhibitors should be titrated to doses
used in clinical trials (as tolerated during
uptitration of other medications, such as
beta blockers).
35. ACEI
CONSENSUS-Enalapril 2.5-40mg (188 days) vs placebo
Pts were already taking digoxin and diuretics
253 Patient with NYHA Class IV
Dec mortality at:
6 months -40%
1 Year – 27%
SOLVD-Enalapril 20mg/day (41 mo)
2569 Patients with and EF <35%
Earlier stages of HF even asymptomatic
NYHA Class II-III
All cause mortality dec by 16%
Morality rate from HF dec by 16%
36.
37. HFSA 2010 Practice Guideline
Angiotensin Receptor Blockers
ARBs are recommended for routine
administration to symptomatic and
asymptomatic patients with an LVEF ≤ 40%
who are intolerant to ACE inhibitors for
reasons other than hyperkalemia or renal
insufficiency.
38. ACEI+ARB
CHARM-Added (Lancet 2003)
2548 NYHA II-IV; LVEF < 40%
CV death, hospital admission
NNT=25
Second study found no benefit
But 23% discontinued due to side effects
(increased cr, hypotension, hyperkalemia)
Currently Ace + Arb is not recommended
39. Nitrates/hydralazine
A combination of hydralazine and isosorbide
dinitrate is recommended as part of standard
therapy, in addition to beta-blockers and ACE-
inhibitors, for African Americans with HF and
reduced LVEF:
NYHA III or IV HF
NYHA II HF
40.
41. Pharmacologic Therapy:
Aldosterone Antagonists
An aldosterone antagonist is recommended
for patients on standard therapy, including
diuretics, who have:
NYHA class IV HF (or class III, previously
class IV) HF from reduced LVEF (≤ 35%)
One should be considered in patients post-MI
with clinical HF or diabetes and an LVEF <
40% who are on standard therapy, including
an ACE inhibitor (or ARB) and a beta blocker.
42. Aldosterone receptor antagonsists
Spironolactone (Aldactone; RALES 1999)
Pts 1,663 Class III/IV, ACE, Loop,Dig, EF < 35%
Decreased all cause mortality of 30%, NNT=10
Hyperkalemia, gynecomastia
Eplerenone (Inspra; EPHESUS 2003)
Pts 6,642 asym LV dysfunction, DM, or after MI
Dec CV mortality of 13%, NNT=43
Newer more selective inhibitor; fewer side effects
More pts on beta-blockers
43. Aldosterone Antagonists and Renal
Function
Aldosterone antagonists are not recommended when:
Creatinine > 2.5mg/dL (or clearance < 30 mL/min)
Serum potassium> 5.0 mmol/L
Therapy includes other potassium-sparing
diuretics
It is recommended that potassium be measured at
baseline, then 1 week, 1 month, and every 3 months
Supplemental potassium is not recommended unless
potassium is < 4.0 mmol/L Strength
44. Digoxin
Digoxin, given in combination with a diuretic
and an ACE inhibitor to people with heart failure
(NYHA grades II-IV) in normal sinus rhythm, has
been found to reduce hospitalization and clinical
deterioration, but not mortality
Consider digoxin if the person continues to be
symptomatic despite adequate doses of diuretic
and ACE inhibitor
Give digoxin to all people with heart failure
and atrial fibrillation who need control of the
ventricular rate.
45. So Mr Abdallah is going home
Which of the following medications has not been
shown to improve mortality in patients with
systolic heart failure?
1. Beta Blocker
2. ACEI
3. Aldosterone antagonist
4. Digoxin
5. ARB
46. What discharge instructions do we
give MR Abdallah
Low salt diet <2gm/day
No Faseekh or maloo7a
Take medications
Weigh yourself everyday
If weight increases over 3-5lb take extra lasix
dose and contact doctor
47. Mr Abdallah wishes to know if
there are any drugs he needs to
avoid
NSAIDs
Most antiarrhythmics
Most calcium channel blockers
Thiazolidinediones e.g Actos, Avandia
48. Further testing??
Remember presumed LV systolic dysfunction
from tachycardia and HTN
But has risk factors for CAD
So will need a coronary angiogram
49. Mr Abdallah underwent coronary angiogram
and showed no significant CAD,
Now what…………..
A. Continue with medical therapy only
B. Repeat echo in 1 year
C. Repeat echo in 3 months
D. Refer for Biv/ICD immediately
50. Device Therapy:
Prophylactic ICD Placement
Prophylactic ICD placement should be
considered in patients with an LVEF ≤35%
and mild to moderate HF symptoms:
Ischemic etiology
Non-ischemic etiology
Today I will mostly focus on systolic heart failure
Initiation of a beta blocker prior to hospital discharge is safe and well tolerated in the majority of patients and dramatically improves utilization of this evidence-based therapy following discharge.